Skip to main content

Table 1 Patients characteristics

From: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

 N° (%)
386
Age (years)
 Median68
 Range21–88
 Elderly (≥ 70)170 (44)
Sex
 Male260 (67.4)
 Female126 (32.6)
ECOG PS
 0–1338 (87.6)
 ≥ 248 (12.4)
Primary tumor
 NSCLC156 (40.4)
 Melanoma163 (42.2)
 Renal cell carcinoma59 (15.3)
 Others8 (2.1)
No. of metastatic sites
 ≤ 2219 (56.7)
 > 2167 (43.3)
Type of anti-PD-1/PD-L1 agent
 Pembrolizumab120 (31.1)
 Nivolumab253 (65.5)
 Atezolizumab10 (2.6)
 Others3 (0.8)
Treatment line of immunotherapy
 First137 (35.5)
 Non-first249 (64.5)